0211-6995 0211-6995 S0211-69952017000300253 10.1016/j.nefro.2016.11.007 España Spain España España España Spain 00 06 2017 00 06 2017 37 3 253 266

2016 16 ^s2 ^s2 2 11-46 2007 357 2562-75 2011 26 15-7 2010 89 851 2011 306 1891-901 2011 92 303-10 2006 20 1-18 2010 23 959-66 2009 2 9-21 2013 27 97-110 2016 30 3-12 2014 46 2035-44 2016 16 2117-38 2012 25 592-602 CRADUS09 Study Group 2008 85 821-6 2010 10 1401-13 2013 95 933-42 2016 2014 14 2106-19 2016 14 152 2003 349 847-58 2012 93 503-8 2011 24 30-42 2011 31 27-34 2016 68 80-91 A2310 IVUS Substudy Investigators 2013 1 389-99 SCHEDULE (SCandinavian HEart transplant everolimus De novo stUdy with earLy calcineurin inhibitors avoidancE) Investigators 2015 15 1967-75 2004 24 112-23 Rapamune Maintenance Regimen Study Group 2006 17 581-9 2012 366 520-9 2015 11 373-83 2012 93 1075-85 Spanish Society of Transplantation Virological and Immune Response Investigation Study Group 2016 18 819-31 2011 1 2453-62 2015 15 2655-64 2009 88 1161-8 2016 29 315-22 ZEUS Study Investigators 2015 15 119-28 2011 92 410-8 1997 64 32-5 156 Study Group 2004 78 1332-40 2009 88 1194-202 2009 88 69-76 2011 24 613-8 2014 6 45-54 2012 25 1106-16 2014 97 405-12 1999 68 1100-6 2014 31 22-32 2010 89 994-1000 2014 19 337-45 2002 73 920-5 2005 27 666-76 2013 27 217-26 2016 38 143-69 2009 9 1876-85 2003 3 1128-34 2013 2 14 2015 29 1021-8 2015 10 e0135439 2004 77 275-80 2013 27 E625-35 2010 33 52-9 2009 87 296-302 2010 23 1084-93 2012 94 547-61 2008 40 3034-6 The Sirolimus Global Clinical UTILY Trial Group 2002 2 ^s3 ^s3 3 470 The Rapamune long-term extension study group 2002 2 ^s3 ^s3 3 396 2016 28 126-33 2006 81 1234-48 2008 22 125-30 2006 82 368-74 2007 20 27-36 2013 13 442-9 2004 77 1215-20 2010 42 3053-4 2010 42 3050-2 2014 27 428-36 2011 ^ss2 ^ss2 s2 58 2012 12 1192-8 2012 12 2561-2 2013 27 455-62 2016 29 41-50 2016